NCT04315896View on ClinicalTrials.gov

Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

April 14, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

August 15, 2020

Conditions
COVID-19Severe Acute Respiratory Syndrome
Interventions
DRUG

Hydroxychloroquine

hydroxychloroquine 400mg day for 10 days

DRUG

Placebo oral tablet

Placebo oral tablet

Trial Locations (1)

14080

"Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas", Mexico City

All Listed Sponsors
lead

National Institute of Respiratory Diseases, Mexico

OTHER_GOV

NCT04315896 - Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) | Biotech Hunter | Biotech Hunter